Select Publications
Journal articles
, 2026, 'Comprehensive Multiplatform Tyrosine Kinase Profiling Reveals Novel Actionable FGFR Aberrations across Sarcomas Affecting the Young', Molecular Cancer Therapeutics, 25, pp. 1077 - 1094, http://dx.doi.org/10.1158/1535-7163.mct-25-0736
, 2026, 'Patient-derived epithelial cell organoids mimic the phenotypic complexity of endometriosis subtypes', Human Reproduction, 41, pp. 262 - 274, http://dx.doi.org/10.1093/humrep/deaf230
, 2026, 'Increasing Gender Affirming Content in the Australian Gynaecology Curriculum: A Commentary', Women S Reproductive Health, 13, pp. 276 - 291, http://dx.doi.org/10.1080/23293691.2025.2508978
, 2025, 'Endometriosis is not the endometrium: Reviewing the over-representation of eutopic endometrium in endometriosis research', , 14, pp. e103825, http://dx.doi.org/10.7554/elife.103825
, 2025, 'An integrated multimodal approach to drug repurposing in endometriosis, using ROR1 as a target', Frontiers in Pharmacology, 16, http://dx.doi.org/10.3389/fphar.2025.1716062
, 2024, 'Medical management of endometriosis', Current Opinion in Obstetrics and Gynecology, 36, pp. 353 - 361, http://dx.doi.org/10.1097/GCO.0000000000000983
, 2023, 'High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer', Cancer Research, 83, pp. 2716 - 2732, http://dx.doi.org/10.1158/0008-5472.CAN-22-3702
, 2022, 'Author Correction: ROR1 is upregulated in endometrial cancer and represents a novel therapeutic target (Scientific Reports, (2020), 10, 1, (13906), 10.1038/s41598-020-70924-z)', Scientific Reports, 12, http://dx.doi.org/10.1038/s41598-022-15043-7
, 2020, 'ROR1 is upregulated in endometrial cancer and represents a novel therapeutic target', Scientific Reports, 10, http://dx.doi.org/10.1038/s41598-020-70924-z
, 2019, 'Circulating cell-free DNA from plasma undergoes less fragmentation during bisulfite treatment than genomic DNA due to low molecular weight', Plos One, 14, http://dx.doi.org/10.1371/journal.pone.0224338
Conference Papers
, 2024, 'ZERO and beyond: Establishment, Characterisation, and Utilisation of Nine Novel Patient-Derived Osteosarcoma Cell Lines', Sydney, Australia, presented at ZERO Childhood Cancer National Symposium “Precision in Action: Collaboration Driving Cancer Breakthroughs", Sydney, Australia, 08 May 2024
, 2022, 'Optimisation of functional in vitro patient-derived osteosarcoma cell culture models', Sydney, presented at Children’s Cancer Institute - Research Symposium 2022, Sydney, 06 December 2022
, 2021, 'Multi-platform tyrosine kinase profiling reveals novel molecular response signatures to FGFR-inhibitors in paediatric and AYA sarcoma.', Virtual, presented at The Australian Society for Medical Research (ASMR) 2021, Virtual, 10 June 2021
Conference Posters
, 2025, 'The potential of ROR1 as a novel therapeutic target for endometriosis', Sydney, Australia, presented at 16th World Congress on Endometriosis, Sydney, Australia, 21 May 2025 - 24 May 2025
, 2023, 'Guiding precision medicine research in endometriosis and adenomyosis via a clinically informed tissue microarray', Edinburgh, Scotland, presented at 15th World Congress on Endometriosis, Edinburgh, Scotland, 03 May 2023 - 06 May 2023
Conference Presentations
, 2026, 'Clinical Heterogeneity Seen Surgically is Reflected at a Cellular Level Using Single-Cell Spatial Maps of Endometriosis', presented at Australasian Gynaecological Endoscopy and Surgery Annual Scientific Meeting 2026, Auckland, New Zealand, 12 March 2026 - 14 March 2026
Conference Abstracts
, 2020, 'Abstract 2942: ROR1: A novel target in endometrial cancer', in Cancer Research, American Association for Cancer Research (AACR), Vol. 80, pp. 2942 - 2942, http://dx.doi.org/10.1158/1538-7445.am2020-2942
Theses / Dissertations
, 2026, Towards Personalised Medicine in Endometriosis: Creating Clinically Defined and Phenotype-Specific Models of Endometriosis, http://dx.doi.org/10.26190/unsworks/32159